Abstract
Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 335-338 |
| Number of pages | 4 |
| Journal | Investigational New Drugs |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1984 |
Fingerprint
Keywords
- 4′-(9-acridinyl-amino)methanesulfon-m-anisidide
- adenocarcinoma of the endometrium
- m-AMSA
- Phase II clinical trial
ASJC Scopus subject areas
- Pharmacology
- Molecular Medicine
Cite this
m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study. / Hilgers, Robert D.; Legha, Sewa S.; Johnston, George A.; Alberts, David S; Stephens, Ronald L.; Tranum, Bill L.; Hannigan, Edward V.
In: Investigational New Drugs, Vol. 2, No. 3, 09.1984, p. 335-338.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - m-AMSA and adenocarcinoma of the endometrium - A Southwest Oncology Group Study
AU - Hilgers, Robert D.
AU - Legha, Sewa S.
AU - Johnston, George A.
AU - Alberts, David S
AU - Stephens, Ronald L.
AU - Tranum, Bill L.
AU - Hannigan, Edward V.
PY - 1984/9
Y1 - 1984/9
N2 - Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.
AB - Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.
KW - 4′-(9-acridinyl-amino)methanesulfon-m-anisidide
KW - adenocarcinoma of the endometrium
KW - m-AMSA
KW - Phase II clinical trial
UR - http://www.scopus.com/inward/record.url?scp=0021229501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021229501&partnerID=8YFLogxK
U2 - 10.1007/BF00175388
DO - 10.1007/BF00175388
M3 - Article
C2 - 6548984
AN - SCOPUS:0021229501
VL - 2
SP - 335
EP - 338
JO - Investigational New Drugs
JF - Investigational New Drugs
SN - 0167-6997
IS - 3
ER -